Using retro 3D glasses and my telephoto lens I took a surprisingly bad photo of the partial solar eclipse, but at least this ...

Chardan lowered the firm’s price target on Century Therapeutics (IPSC) to $7 from $11 and keeps a Buy rating on the shares. The company ...

“We have made the strategic decision to discontinue the Phase 1 ELiPSE-1 trial early, and we thank the patients, providers and caregivers for their support and participation. We believe CNTY-101 ...

PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell ...

The company is discontinuing the Phase 1 ELiPSE-1 trial due to insufficient data for its late-stage NHL program, while expanding the CALiPSO-1 trial in the U.S. and Europe. The company is also ...